Gamida Cell is a clinical-stage biopharmaceutical company committed to developing novel cell therapies with the potential to cure difficult-to-treat cancers and rare, serious hematologic diseases. We are leveraging our proprietary nicotinamide-based cell expansion technology, or NAM technology, to develop product candidates designed to address the limitations of cell therapies.
Our lead clinical program, NiCord®, has the potential to serve as a universal, curative bone marrow transplant for patients with certain high-risk blood cancers and bone marrow failure disorders. NiCord is currently being evaluated in a Phase 3 study in patients with high-risk blood cancers as well as in a Phase 1/2 study in patients with severe aplastic anemia.
Beyond NiCord, we are leveraging our NAM technology to develop NAM-NK, which harnesses the power of the anti-tumor properties found within natural killer (NK) cells. NAM-NK has the potential to serve as a universal donor-based therapy when combined with standard-of-care therapeutic antibodies. The NAM-NK program is currently being evaluated in an investigator-sponsored, Phase 1 study in patients with refractory non-Hodgkin lymphoma or multiple myeloma.